Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models

Using an unbiased, combinatorial, high-throughput drug screen, we identified the combination of co-targeting Bcl-xL and Mcl-1 to be highly synergistic across AR-V7-expressing CRPC models. We showed efficacy in higher-order models through validation across in vitro models spanning two-dimensional cell culture, three-dimensional cell culture, and a patient-derived organoid model. These findings identify a promising therapeutic strategy for patients with AR-V7-expressing CRPC.

Authors

Institutions

Publication Details

Journal
Cancer Research Communications
Published
2025-07-24
DOI
https://doi.org/10.1158/2767-9764.crc-25-0096
Citations
1
Primary Topic
Protein Degradation and Inhibitors
Type
article
Field-Weighted Citation Impact
0.81

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models

Kelli M. Wilson, Erin Beck, Andres F. Leon, Craig J. Thomas et al.
1 citations
Cancer Research Communications
Protein Degradation and Inhibitors
0.81
article

Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models

Kelli M. Wilson, Erin Beck, Andres F. Leon, Craig J. Thomas, Kinjal Bhadresha, Xiaohu Zhang, Keith Thomas Schmidt, Jessica D. Kindrick, Adam G. Sowalsky, Carleen Klumpp‐Thomas, Michele Ceribelli, Erica L. Beatson, Crystal McKnight, Giulia C. Napoli, Douglas K. Price, William D. Figg, Emily N. Risdon, JuanJuan Yin, Cindy H. Chau, Benjamin C. Brim
article en
1 citations

Abstract

Using an unbiased, combinatorial, high-throughput drug screen, we identified the combination of co-targeting Bcl-xL and Mcl-1 to be highly synergistic across AR-V7-expressing CRPC models. We showed efficacy in higher-order models through validation across in vitro models spanning two-dimensional cell culture, three-dimensional cell culture, and a patient-derived organoid model. These findings identify a promising therapeutic strategy for patients with AR-V7-expressing CRPC.

Cancer Research CommunicationsVol. 5(8)
National Institutes of Health (US), National Cancer Institute (US), National Center for Advancing Translational Sciences (US)
U.S. Department of Health and Human Services
Good health and well-being
Openalex Percentile: Top 25%
Protein Degradation and Inhibitors
0.81
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.